Indaptus Therapeutics develops proprietary therapeutics by exploiting bacteria's natural ability to engage the human immune system. The company utilizes patented, attenuated, and killed non-pathogenic gram-negative bacteria to activate innate and adaptive immune responses. This approach demonstrates potential anti-tumor and anti-viral activity for disease treatment.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and infectious disease treatments often fail to fully engage the body's immune system, limiting their effectiveness and leading to incomplete responses. Many existing immunotherapies activate only a limited number of innate or adaptive immune cell types, leaving other crucial pathways untapped. There is a need for therapies that can safely and effectively activate a broader range of immune responses to eradicate tumors and combat viral infections.
Solution
Indaptus Therapeutics develops attenuated, non-pathogenic bacterial therapies designed to activate both innate and adaptive immune responses to fight cancer and infectious diseases. Their platform leverages specific bacterial strains with unique levels of lipopolysaccharide (LPS) to elicit a broad immune response by targeting multiple immune receptors, including Toll-like (TLR), NOD, STING, and RIG-I. The company's lead candidate, Decoy20, has demonstrated in pre-clinical studies the ability to synergize with existing therapies, such as checkpoint inhibitors and targeted antibodies, to produce durable anti-tumor responses and induce immunological memory. By passively targeting both the tumor and immune organs, Indaptus aims to create widely accessible treatments with broad anti-tumor and anti-viral activity, independent of specific tumor or viral antigens.
Target Audience
The primary target audience includes patients with advanced or metastatic solid tumors and individuals with chronic viral infections, as well as clinicians and researchers seeking novel immunotherapeutic approaches.
Features
- Proprietary platform based on attenuated and killed non-pathogenic gram-negative bacteria
- Multi-targeted approach activating both innate and adaptive cellular immunity
- Exploits bacterial pathogen-associated molecular patterns (PAMPs) to stimulate immune receptors
- Decoy20, the lead candidate, is currently in Phase 1 clinical trials for advanced/metastatic tumors
- Demonstrated synergistic activity with checkpoint inhibitors, NSAIDs, and targeted antibodies in pre-clinical models
- Induces immunological memory for durable anti-tumor responses
- Passively targets the liver, spleen, and tumor vasculature for broad immune activation
- Designed for intravenous delivery with rapid clearance to minimize autoimmune side effects